Exploratory Study to Evaluate Efficacy and Safety of GC012F Injection in Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
Latest Information Update: 05 Oct 2022
At a glance
- Drugs AZD 0120 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 21 Sep 2021 Planned initiation date changed from 1 Dec 2020 to 1 Dec 2021.
- 09 Nov 2020 New trial record